Infervision, a Beijing, China-based artificial intelligence company developing medical imaging technology, raised $47 million in series B+ financing from existing and new investors, according to China Money Network.
Here are four things to know.
1. The Chinese medical imaging company was founded in 2016 to apply deep learning technology to medical imaging. Its product AI-CT is designed to identify the chief traits of lung cancer and detect suspicious lesions through CT scans.
2. Infervision's AI-DR is intended to target cardiothoracic lesions, reducing digital radiography analysis time from ten minutes to five seconds.
3. The company claims to have partnered with half of the hospitals on Fudan University's Top Hospital List, serving about 450,000 patients. Outside of China, Infervision has set up offices in the U.S., Japan and Germany to prepare for global development.
4. Existing investors include Sequoia Capital China, Qiming Venture Partners and Genesis Capital. New investors in the round include venture capital firm Xianghe Capital and Advantech Capital.
More articles on imaging:
Trump's proposed 2019 budget calls for $71M for 145 CT airport scanners: 5 things to know
Unsafe radiation exposure from mini-C arm fluoroscopy: 7 things to know